Zhou Xiaohu, Zhang Linshi, Zheng Bichun, Yan Yingcai, Zhang Yuan, Xie Haiyang, Zhou Lin, Zheng Shusen, Wang Weilin
Key Lab of Combined Multi-Organ Transplantation, Ministry of Public Health, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Cancer Sci. 2016 Apr;107(4):424-32. doi: 10.1111/cas.12904. Epub 2016 Mar 30.
Hepatocellular carcinoma (HCC) is the sixth most prevalent cancer and the third leading cause of cancer-related deaths worldwide. The fate of a cell is determined by the balance between the processes of fission and fusion that constantly occur in the mitochondria of cells. We previously showed that overexpression of Mitofusin-2 can induce apoptosis in HCC cells by triggering an influx of Ca(2+) into the mitochondria from the ER. The function of Mitofusin-2 has been studied extensively, but the mechanism underlying the post-transcriptional regulation of Mitofusin-2 has not been elucidated. In the present study, we aimed to identify the mechanism of Mitofusin-2 regulation in HCC. We demonstrated that Mitofusin-2 is a direct target of miR-761, which was found to be upregulated in HCC tissues. Furthermore, a miR-761 inhibitor impaired mitochondrial function by upregulating Mitofusin-2 and effectively repressed tumor growth and metastasis both in vivo and in vitro. Our findings provide new insight into the mechanism underlying Mitofusin-2 regulation and the potential role of miR-761 in HCC, making it a potential candidate for use in HCC therapy in the future.
肝细胞癌(HCC)是全球第六大常见癌症,也是癌症相关死亡的第三大主要原因。细胞的命运由细胞线粒体内不断发生的裂变和融合过程之间的平衡决定。我们之前表明,线粒体融合蛋白2(Mitofusin-2)的过表达可通过触发钙离子从内质网流入线粒体来诱导肝癌细胞凋亡。Mitofusin-2的功能已得到广泛研究,但其转录后调控的机制尚未阐明。在本研究中,我们旨在确定肝癌中Mitofusin-2的调控机制。我们证明Mitofusin-2是miR-761的直接靶点,miR-761在肝癌组织中上调。此外,miR-761抑制剂通过上调Mitofusin-2来损害线粒体功能,并在体内和体外有效抑制肿瘤生长和转移。我们的研究结果为Mitofusin-2调控机制以及miR-761在肝癌中的潜在作用提供了新的见解,使其成为未来肝癌治疗的潜在候选药物。